Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
Status:
Completed
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well eribulin mesylate works in treating patients with
osteosarcoma that has come back after treatment (recurrent) or has not responded to treatment
(refractory). Microtubule inhibitors, such as eribulin mesylate, may stop or slow the growth
of tumor cells by disrupting the cell cycle.